- Home
- BNTX vs FCNCA Comparison
BNTX vs FCNCA Comparison
Compare BNTX & FCNCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNTX | FCNCA |
|---|---|---|
| Founded | 2008 | 1898 |
| Country | Germany | United States |
| Employees | N/A | 17475 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 27.0B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BNTX | FCNCA |
|---|---|---|
| Price | $108.22 | $2,169.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $140.31 | ★ $2,172.89 |
| AVG Volume (30 Days) | ★ 1.1M | 74.8K |
| Earning Date | 11-03-2025 | 01-23-2026 |
| Dividend Yield | N/A | ★ 0.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 169.29 |
| Revenue | $3,698,814,972.00 | ★ $8,897,000,000.00 |
| Revenue This Year | $2.03 | $3.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.81 |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $81.20 | $1,473.62 |
| 52 Week High | $126.77 | $2,412.93 |
Technical Indicators
Market Signals| Indicator | BNTX | FCNCA |
|---|---|---|
| Relative Strength Index (RSI) | 70.02 | 65.51 |
| Support Level | $105.16 | $2,130.14 |
| Resistance Level | $109.28 | $2,193.05 |
| Average True Range (ATR) | 2.35 | 37.92 |
| MACD | 1.52 | -11.60 |
| Stochastic Oscillator | 83.23 | 48.49 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About FCNCA First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of over $230 billion as of Sept. 30, 2025. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of making troubled bank acquisitions from the FDIC, like the 2023 acquisition of Silicon Valley Bridge Bank, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2024.